NanoSyrinx is the first company to engineer ‘nanosyringes’, a selective non-viral peptide and protein delivery system identified in an undisclosed organism.
The company will focus on direct cytosolic delivery of genome editing enzymes and therapeutic proteins in vivo, with key applications in the cell and gene therapy space. NanoSyrinx is developing a fully customisable genetic platform that selectively delivers peptide and protein payloads – including functional gene editing enzymes and nucleases – directly to the cytosol of targeted cells. The system was first identified by the Waterfield Lab based at Warwick Medical School at the University of Warwick. NanoSyrinx Ltd was founded in 2020 following the completion of an extensive international market validation exercise under the ICURe programme, funded by Innovate UK. The platform developed by the team offers a unique combination of features, overcoming challenges such as payload limitations and manufacturing complexities, which has limited the adoption of other intracellular delivery approaches.
NanoSyrinx’s initial focus will be on the development of its ex vivo gene editing nanosyringe concept, having already engaged with a number of leaders in the cell therapy field.
